European Approval for Glaxos Tafinlar

New Drug Approvals

 

European Approval for Glaxos Tafinlar

 


Zacks.com

GlaxoSmithKline (GSKAnalyst Report) recently announced that its melanoma drug, Tafinlar, has been cleared by the European Commission (EC). Tafinlar is indicated as a monotherapy for treating adults suffering from unresectable or metastatic melanoma with a BRAF V600 mutation


The approval came on the basis of encouraging data from several multi-center global trials including the phase III BREAK-3 study. We remind investors that Currently approved melanoma drugs include Zelboraf and Yervoy. Glaxo carries a Zacks Rank #3 http://www.zacks.com/stock/news/108341/european-approval-for-glaxos-tafinlar

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s